Access to Medicines – Page 27

Statement on Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

September 25, 2022April 2, 2004

HIV/AIDS and Pharmaceutical Pricing

September 25, 2022March 31, 2004

This info sheet is one in a series of seven info sheets on the federal regulation of pharmaceutical prices in Canada. Health Spending and the Pharmaceutical Industry Controlling Medicine Prices: Evolution of Canadian Law Patented Medicine Prices Review Board Preventing Excessive Pricing of Patented Medicines Jurisdiction of the PMPRB Pricing of HIV/AIDS Drugs Trends in … Read more

Letter to the Standing Committee on Industry, Science and Technology re: Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

September 25, 2022March 26, 2004

“I write to follow up on our previous submissions to the Standing Committee regarding Bill C-9, Canada’s laudable initiative to implement the WTO General Council Decision of August 30, 2003 to enable countries lacking sufficient pharmaceutical manufacturing capacity to ‘make effective use’ of compulsory licensing to obtain lower cost generic pharmaceutical products manufactured in Canada…”

Letter to the Standing Committee on Industry, Science and Technology re: Bill C-9 and the issue of NGO procurement of Canadian-made phramaceuticals

September 25, 2022March 23, 2004

“As was requested by the Committee when we appeared before you on February 26, 2004, we have provided the Committee with our supplementary submissions regarding the alternatives to the ‘right of refusal’ that had been proposed to the Committee… “However, discussions at subsequent Committee meetings have indicated that Committee members are under a fundamental misapprehension … Read more

Global Access to Medicines: Will Canada Meet the Challenge? – Supplementary submission to the Standing Committee on Industry, Science and Technology regarding Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

September 25, 2022March 8, 2004

The Standing Committee has asked that we provide our views regarding the “alternatives” to the right of refusal that have been put forward by other witnesses appearing before the Committee. We address several of the most important points that have been put before the Committee.

Amending Canada’s Drug Patent Law: A betrayal of patients in developing countries

September 25, 2022February 26, 2004

Global Access to Medicines: Will Canada Meet the Challenge? – A Submission to the Standing Committee on Industry, Science and Technology regarding Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

September 25, 2022February 26, 2004

Bill C-9 is Canada’s legislation to implement the WTO General Council Decision of 30 August 2003. The bill, therefore, should fully reflect the flexibility that the WTO Decision creates for countries to use compulsory licensing to import cheaper, generic phramaceutical products.

Affordable Generic Medicines for Developing Countries: Promise in Speech from Throne, but true commitment requires effective bill

September 25, 2022February 2, 2004

Affordable Generic Medicines for Developing Countries: Prime Minister’s commitment is welcome, but bill is flawed and must be fixed

September 25, 2022January 23, 2004

TRIPS from Doha to Cancún . . . to Ottawa: global developments in access to treatment and Canada’s Bill C-56 — HIV/AIDS Policy & Law Review 8(3)

October 4, 2022December 1, 2003

In November 2003, Canada introduced legislation to amend the Patent Act so that manufacturers could obtain licences to make generic versions of patented pharmaceutical products for export to countries lacking sufficient capacity to produce their own. This article provides an overview of recent global developments leading up to Canada’s initiative, as well as an analysis … Read more